Core Viewpoint - Haier Biomedical held the 2026 Ecological Partner Co-Creation Summit, unveiling three core strategies: AI+ Innovation, Science and Technology Co-Creation, and a New Era of Channels, while signing the "AI Autonomous Laboratory" ecological cooperation agreement with eight leading enterprises to build a new ecosystem in life sciences [2][3][12]. Group 1: AI+ Innovation Strategy - The AI+ Innovation strategy aims to reconstruct intelligent productivity in life sciences by creating an ecosystem that integrates AI, data, robotics, equipment, and applications, facilitating a transition from service processes to enhanced productivity and precision discovery [9]. - Haier Biomedical's CTO introduced the "AutoLab Mind" intelligent brain as the core of a four-layer intelligent architecture, enabling cognitive decision-making in laboratory settings and streamlining process collaboration and data management [9]. Group 2: Science and Technology Co-Creation - The Science and Technology Co-Creation strategy focuses on breaking down barriers between research and application, transforming clinical research pain points into product innovation starting points through collaboration with top research institutions and local agents [6][7]. - A roundtable forum was held to discuss how to promote Chinese solutions globally, featuring representatives from various medical and research institutions [6][7]. Group 3: New Era of Channels - The New Era of Channels strategy emphasizes the importance of ecological integration, scene responsiveness, and user operation capabilities in future competition, moving away from traditional pricing models to a user value contribution commission model [13]. - This model encourages distributors to become innovators in their fields, driving self-evolution and achieving mutual benefits [13]. Group 4: Strategic Partnerships - Haier Biomedical signed strategic cooperation agreements with eight leading enterprises, including Shunfeng Pharmaceutical and Southeast University, to accelerate the construction of a full lifecycle service loop from research to clinical application [7][10]. - The company aims to leverage these partnerships to enhance its capabilities in the life sciences sector and promote technological innovation [7][10]. Group 5: Global Business Expansion - Haier Biomedical has established a presence in over 160 countries and regions, maintaining long-term collaborations with nearly 80 international organizations, including WHO and UNICEF, positioning itself as a leader in the global life sciences laboratory equipment market [15]. - The company focuses on green development and has received multiple certifications, reinforcing its commitment to sustainable practices in the industry [15].

Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, covering low-temperature storage, smart medication, blood technology, and laboratory solutions [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1] Business Transformation - The revenue share from new industries (smart medication, blood technology, laboratory solutions, etc.) increased from 38% in 2023 to 47% in the first half of 2025, a year-on-year increase of 7.27 percentage points [1] International Expansion - The company's products are now available in over 150 countries and regions, with five new localized platforms established in Japan, Brazil, and others during the reporting period [1] - The localized strategy has shown significant results, with overseas revenue growing by over 30% year-on-year, and the second quarter's revenue scale and growth rate reaching a new high for 2023 [1]